Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | NQO2 | P16083 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2838267 | 0.83 | ALDH1A1 (0.39) | ESR1ESR2NQO2ALDH1A1TSHR | |
| SCHEMBL15268291 | 0.79 | KDM4E (0.49) | NQO2ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL2237640 | 0.78 | NQO2 (0.35) | ESR1ESR2NQO2ALDH1A1TSHR | |
| SCHEMBL2242688 | 0.76 | IDO1 (0.42) | ESR2KDM4EKMT2ATDO2MEN1 | |
| SCHEMBL2838373 | 0.76 | MEN1 (0.39) | NQO2ALDH1A1TSHRKDM4EHSD17B10 | |
| SCHEMBL2836126 | 0.76 | TDO2 (0.46) | NQO2ALDH1A1L3MBTL1KDM4EKMT2A | |
| SCHEMBL2216607 | 0.75 | NPC1 (0.40) | ALDH1A1KDM4EHPGDHSD17B10KMT2A | |
| SCHEMBL2216620 | 0.74 | TDO2 (0.42) | ALDH1A1L3MBTL1KDM4EKMT2ATDO2 | |
| SCHEMBL8087290 | 0.73 | LMNA (0.47) | NQO2ALDH1A1TSHRL3MBTL1KDM4E | |
| SCHEMBL2213375 | 0.73 | PDE1B (0.38) | ESR1ESR2NQO2ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7659245-B2 | Macrocylic inhibitors of hepatitis C virus | TIBOTEC PHARMACEUTICALS LTD (IE) | 2010-02-09 | — | — | US | disclosed |
| US-7659245-B2 | Macrocylic inhibitors of hepatitis C virus | TIBOTEC PHARMACEUTICALS LTD (IE) | 2010-02-09 | — | — | US | disclosed |
| US-7659245-B2 | Macrocylic inhibitors of hepatitis C virus | TIBOTEC PHARMACEUTICALS LTD (IE) | 2010-02-09 | — | — | US | disclosed |
| EP-1912981-B1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARM LTD (IE) | 2010-01-20 | — | — | EP | disclosed |
| EP-1912981-B1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARM LTD (IE) | 2010-01-20 | — | — | EP | disclosed |
| US-20090118312-A1 | Macrocylic Inhibitors of Hepatitis C Virus | JANSSEN SCIENCES IRELAND UC (IE) | 2009-05-07 | — | — | US | disclosed |
| US-20090118312-A1 | Macrocylic Inhibitors of Hepatitis C Virus | JANSSEN SCIENCES IRELAND UC (IE) | 2009-05-07 | — | — | US | disclosed |
| US-20090118312-A1 | Macrocylic Inhibitors of Hepatitis C Virus | JANSSEN SCIENCES IRELAND UC (IE) | 2009-05-07 | — | — | US | disclosed |
| EP-1912981-A2 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | Tibotec Pharmaceuticals Ltd. (IE) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007014927-A2 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007014927-A2 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118312-A1 | Macrocylic Inhibitors of Hepatitis C Virus | CBR1, HAVCR2, AOC1 | ESR1 3257/4885ESR2 2428/4885NQO2 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.